OncoGenex Pharmaceuticals, Inc. (OGXI)
-NasdaqCM 10.64 
0.47(4.62%) 4:00PM EDT|After Hours
:
10.64 0.00 (0.00%) 4:37PM EDT
| Prev Close: | 10.17 |
|---|
| Open: | 10.40 |
|---|
| Bid: | 8.30 x 100 |
|---|
| Ask: | 14.50 x 9500 |
|---|
| 1y Target Est: | 26.07 |
|---|
| Beta: | 1.81 |
|---|
| Next Earnings Date: | 2-Aug-13 |
|---|
| Day's Range: | 10.14 - 10.74 |
|---|
| 52wk Range: | 9.16 - 14.99 |
|---|
| Volume: | 86,809 |
|---|
| Avg Vol (3m): | 68,175 |
|---|
| Market Cap: | 156.09M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.43 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung CancerCNW Group(Thu 6:30AM EDT)
- OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung CancerPR Newswire(Thu 6:30AM EDT)
- InPlay: OncoGenex Pharma announces multiple 'trials in progress' presentations at the 2013 ASCO annual meetingBriefing.com(Wed, May 22)
- OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual MeetingCNW Group(Wed, May 22)
- OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual MeetingPR Newswire(Wed, May 22)
- ONCOGENEX PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 10)
- OncoGenex Loss Lower than ExpectedZacks(Mon, May 6)
- OncoGenex Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 3)
- OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013CNW Group(Thu, May 2)
- OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013PR Newswire(Thu, May 2)
- ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatemenEDGAR Online(Thu, May 2)
- Q1 2013 Oncogenex Pharmaceuticals, Inc. Earnings Release - After Market CloseCCBN(Thu, May 2)
- OncoGenex Pharmaceuticals Becomes Oversold (OGXI)at TheStreet(Wed, May 1)
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerPR Newswire(Wed, May 1)
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerCNW Group(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6.25 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.47 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.62 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of cancer therapies that address treatment resistance in cancer patients.
View More